These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12183594)

  • 21. Human IgG subclass antibodies to the 19 kilodalton carboxy terminal fragment of Plasmodium falciparum merozoite surface protein 1 (MSP1(19)) and predominance of the MAD20 allelic type of MSP1 in Uganda.
    Apio B; Nalunkuma A; Okello D; Riley E; Egwang TG
    East Afr Med J; 2000 Apr; 77(4):189-93. PubMed ID: 12858901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia.
    Okech BA; Corran PH; Todd J; Joynson-Hicks A; Uthaipibull C; Egwang TG; Holder AA; Riley EM
    Infect Immun; 2004 Mar; 72(3):1557-67. PubMed ID: 14977962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum merozoite surface protein 1 types in individuals in Nigeria with sub-microscopic infection.
    Ngoundou-Landji J; Nwuba RI; Anumudu CI; Odaibo AB; Matondo Maya WD; Awobode HO; Okafor CM; Morenikeji OA; Asinobi A; Nwagwu M; Holder AA; Ntoumi F
    Malar J; 2010 Oct; 9():287. PubMed ID: 20955565
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A malaria vaccine based on the polymorphic block 2 region of MSP-1 that elicits a broad serotype-spanning immune response.
    Cowan GJ; Creasey AM; Dhanasarnsombut K; Thomas AW; Remarque EJ; Cavanagh DR
    PLoS One; 2011; 6(10):e26616. PubMed ID: 22073118
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rice-produced MSP142 of Plasmodium falciparum elicits antibodies that inhibit parasite growth in vitro.
    Chen Q; Liang W; Qian F; Qian B; Cao J; Zhang D; Xu Y; Tang L
    Parasite Immunol; 2016 Oct; 38(10):635-41. PubMed ID: 27493141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
    Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
    Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
    Stanisic DI; Richards JS; McCallum FJ; Michon P; King CL; Schoepflin S; Gilson PR; Murphy VJ; Anders RF; Mueller I; Beeson JG
    Infect Immun; 2009 Mar; 77(3):1165-74. PubMed ID: 19139189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominance of conserved B-cell epitopes of the Plasmodium falciparum merozoite surface protein, MSP1, in blood-stage infections of naive Aotus monkeys.
    Hui GS; Nikaido C; Hashiro C; Kaslow DC; Collins WE
    Infect Immun; 1996 May; 64(5):1502-9. PubMed ID: 8613353
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shift in epitope dominance of IgM and IgG responses to Plasmodium falciparum MSP1 block 4.
    Chang SP; Kayatani AK; Terrientes ZI; Herrera S; Leke RG; Taylor DW
    Malar J; 2010 Jan; 9():14. PubMed ID: 20070906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A polyvalent hybrid protein elicits antibodies against the diverse allelic types of block 2 in Plasmodium falciparum merozoite surface protein 1.
    Tetteh KK; Conway DJ
    Vaccine; 2011 Oct; 29(44):7811-7. PubMed ID: 21820475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat sequences in block 2 of Plasmodium falciparum merozoite surface protein 1 are targets of antibodies associated with protection from malaria.
    Polley SD; Tetteh KK; Cavanagh DR; Pearce RJ; Lloyd JM; Bojang KA; Okenu DM; Greenwood BM; McBride JS; Conway DJ
    Infect Immun; 2003 Apr; 71(4):1833-42. PubMed ID: 12654798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria.
    Holder AA; Guevara Patiño JA; Uthaipibull C; Syed SE; Ling IT; Scott-Finnigan T; Blackman MJ
    Parassitologia; 1999 Sep; 41(1-3):409-14. PubMed ID: 10697894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biological activities of anti-merozoite surface protein-1 antibodies induced by adjuvant-assisted immunizations in mice with different immune gene knockouts.
    Hui G; Choe D; Hashimoto C
    Clin Vaccine Immunol; 2008 Aug; 15(8):1145-50. PubMed ID: 18562564
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunogenicity and in vitro protective efficacy of recombinant Mycobacterium bovis bacille Calmette Guerin (rBCG) expressing the 19 kDa merozoite surface protein-1 (MSP-1(19)) antigen of Plasmodium falciparum.
    Nurul AA; Norazmi MN
    Parasitol Res; 2011 Apr; 108(4):887-97. PubMed ID: 21057812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1.
    Egan AF; Morris J; Barnish G; Allen S; Greenwood BM; Kaslow DC; Holder AA; Riley EM
    J Infect Dis; 1996 Mar; 173(3):765-9. PubMed ID: 8627050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative analysis of the profiles of IgG subclass-specific responses to Plasmodium falciparum apical membrane antigen-1 and merozoite surface protein-1 in naturally exposed individuals living in malaria hypoendemic settings, Iran.
    Rouhani M; Zakeri S; Mehrizi AA; Djadid ND
    Malar J; 2015 Feb; 14():58. PubMed ID: 25652589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Contrasting Patterns of Serologic and Functional Antibody Dynamics to Plasmodium falciparum Antigens in a Kenyan Birth Cohort.
    Dent AE; Malhotra I; Wang X; Babineau D; Yeo KT; Anderson T; Kimmel RJ; Angov E; Lanar DE; Narum D; Dutta S; Richards J; Beeson JG; Crabb BS; Cowman AF; Horii T; Muchiri E; Mungai PL; King CL; Kazura JW
    Clin Vaccine Immunol; 2016 Feb; 23(2):104-16. PubMed ID: 26656119
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum.
    Woehlbier U; Epp C; Kauth CW; Lutz R; Long CA; Coulibaly B; Kouyaté B; Arevalo-Herrera M; Herrera S; Bujard H
    Infect Immun; 2006 Feb; 74(2):1313-22. PubMed ID: 16428781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical-grade 42-kilodalton fragment of merozoite surface protein 1 of Plasmodium falciparum strain FVO expressed in Escherichia coli protects Aotus nancymai against challenge with homologous erythrocytic-stage parasites.
    Darko CA; Angov E; Collins WE; Bergmann-Leitner ES; Girouard AS; Hitt SL; McBride JS; Diggs CL; Holder AA; Long CA; Barnwell JW; Lyon JA
    Infect Immun; 2005 Jan; 73(1):287-97. PubMed ID: 15618165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibodies and Plasmodium falciparum merozoites.
    Ramasamy R; Ramasamy M; Yasawardena S
    Trends Parasitol; 2001 Apr; 17(4):194-7. PubMed ID: 11282510
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.